|
1
|
Nathan DM, Buse JB, Davidson MB, Heine RJ,
Holman RR, Sherwin R and Zinman B: Professional Practice Committee,
American Diabetes Association; European Association for the Study
of Diabetes: Management of hyperglycaemia in type 2 diabetes: A
consensus algorithm for the initiation and adjustment of therapy. A
consensus statement from the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetologia.
49:1711–1721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aljada A and Mousa SA: Metformin and
neoplasia: Implications and indications. Pharmacol Ther.
133:108–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soritau O, Tomuleasa C, Aldea M, Petrushev
B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, et al:
Metformin plus temozolomide-based chemotherapy as adjuvant
treatment for WHO grade III and IV malignant gliomas. J BUON.
16:282–289. 2011.PubMed/NCBI
|
|
4
|
Riedmaier Emami A, Fisel P, Nies AT,
Schaeffeler E and Schwab P: Metformin and cancer: From the old
medicine cabinet to pharmacological pitfalls and prospects. Trends
Pharmacol Sci. 34:126–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campagnoli C, Abbà C, Ambroggio S, Brucato
T and Pasanisi P: Life-style and metformin for the prevention of
endometrial pathology in postmenopausal women. Gynecol Endocrinol.
29:119–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashburn TT and Thor KB: Drug
repositioning: Identifying and developing new uses for existing
drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moiseeva O, Deschênes-Simard X, Pollak M
and Ferbeyre G: Metformin, aging and cancer. Aging (Albany NY).
5:330–331. 2013.PubMed/NCBI
|
|
8
|
Nathan DM, Buse JB, Davidson MB,
Ferrannini E, Holman RR, Sherwin R and Zinman B: American Diabetes
Association; European Association for Study of Diabetes: Medical
management of hyperglycemia in type 2 diabetes: A consensus
algorithm for the initiation and adjustment of therapy: A consensus
statement of the American Diabetes Association and the European
Association for the Study of Diabetes. Diabetes Care. 32:193–203.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bailey CJ: Biguanides and NIDDM. Diabetes
Care. 15:755–772. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stumvoll M, Nurjhan N, Perriello G, Dailey
G and Gerich JE: Metabolic effects of metformin in
non-insulin-dependent diabetes mellitus. N Engl J Med. 333:550–554.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morgan CL, Mukherjee J, Jenkins-Jones S,
Holden SE and Currie CJ: Association between first-line monotherapy
with sulphonylurea versus metformin and risk of all-cause mortality
and cardiovascular events: A retrospective, observational study.
Diabetes Obes Metab. 16:957–962. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan NN, Brain HP and Feher MD:
Metformin-associated lactic acidosis: A rare or very rare clinical
entity? Diabet Med. 16:273–281. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kilo C: Metformin: A safe and effective
treatment in the management of NIDDM. Mo Med. 94:114–123.
1997.PubMed/NCBI
|
|
15
|
Vasisht KP, Chen SC, Peng Y and Bakris GL:
Limitations of metformin use in patients with kidney disease: Are
they warranted? Diabetes Obes Metab. 12:1079–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horlen C, Malone R, Bryant B, Dennis B,
Carey T, Pignone M and Rothman R: Frequency of inappropriate
metformin prescriptions. JAMA. 287:2504–2505. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calabrese AT, Coley KC, DaPos SV, Swanson
D and Rao RH: Evaluation of prescribing practices: Risk of lactic
acidosis with metformin therapy. Arch Intern Med. 162:434–437.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masoudi FA, Wang Y, Inzucchi SE, Setaro
JF, Havranek EP, Foody JM and Krumholz HM: Metformin and
thiazolidinedione use in Medicare patients with heart failure.
JAMA. 290:81–85. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stang M, Wysowski DK and Butler-Jones D:
Incidence of lactic acidosis in metformin users. Diabetes Care.
22:925–927. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saydah SH, Loria CM, Eberhardt MS and
Brancati FL: Abnormal glucose tolerance and the risk of cancer
death in the United States. Am J Epidemiol. 157:1092–1100. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Michels KB, Solomon CG, Hu FB, Rosner BA,
Hankinson SE, Colditz GA and Manson JE: Nurses' Health Study: Type
2 diabetes and subsequent incidence of breast cancer in the Nurses'
Health Study. Diabetes Care. 26:1752–1758. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Will JC, Galuska DA, Vinicor F and Calle
EE: Colorectal cancer: Another complication of diabetes mellitus?
Am J Epidemiol. 147:816–825. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Everhart J and Wright D: Diabetes mellitus
as a risk factor for pancreatic cancer. A meta-analysis. JAMA.
273:1605–1609. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gapstur SM, Gann PH, Colangelo LA,
Barron-Simpson R, Kopp P, Dyer A and Liu K: Postload plasma glucose
concentration and 27-year prostate cancer mortality (United
States). Cancer Causes Control. 12:763–772. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moore MA, Park CB and Tsuda H:
Implications of the hyperinsulinaemia-diabetes-cancer link for
preventive efforts. Eur J Cancer Prev. 7:89–107. 1998.PubMed/NCBI
|
|
26
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bowker SL, Yasui Y, Veugelers P and
Johnson JA: Glucose-lowering agents and cancer mortality rates in
type 2 diabetes: Assessing effects of time-varying exposure.
Diabetologia. 53:1631–1637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Inoki K, Li Y, Zhu T, Wu J and Guan KL:
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR
signalling. Nat Cell Biol. 4:648–657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation - implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stephenne X, Foretz M, Taleux N, van der
Zon GC, Sokal E, Hue L, Viollet B and Guigas P: Metformin activates
AMP-activated protein kinase in primary human hepatocytes by
decreasing cellular energy status. Diabetologia. 54:3101–3110.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gunton JE, Delhanty PJ, Takahashi S and
Baxter RC: Metformin rapidly increases insulin receptor activation
in human liver and signals preferentially through insulin-receptor
substrate-2. J Clin Endocrinol Metab. 88:1323–1332. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sahra Ben I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo
through a decrease of cyclin D1 level. Oncogene. 27:3576–3586.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Calle EE, Rodriguez C, Walker-Thurmond K
and Thun MJ: Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J Med.
348:1625–1638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Navaratnarajah R, Pillay OC and Hardiman
P: Polycystic ovary syndrome and endometrial cancer. Semin Reprod
Med. 26:62–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dronavalli S and Ehrmann DA: Pharmacologic
therapy of polycystic ovary syndrome. Clin Obstet Gynecol.
50:244–254. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dumesic DA and Lobo RA: Cancer risk and
PCOS. Steroids. 78:782–785. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou C, Gehrig PA, Whang YE and Boggess
JF: Rapamycin inhibits telomerase activity by decreasing the hTERT
mRNA level in endometrial cancer cells. Mol Cancer Ther. 2:789–795.
2003.PubMed/NCBI
|
|
41
|
Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y
and Liao QP: Metformin promotes progesterone receptor expression
via inhibition of mammalian target of rapamycin (mTOR) in
endometrial cancer cells. J Steroid Biochem Mol Biol. 126:113–120.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsuji K, Kisu I, Banno K, Yanokura M, Ueki
A, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Susumu N and Aoki
D: Metformin: A possible drug for treatment of endometrial cancer.
Open J Obstet Gynecol. 2:1–6. 2012. View Article : Google Scholar
|
|
43
|
Ko EM, Walter P, Jackson A, Clark L,
Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA
and Bae-Jump V: Metformin is associated with improved survival in
endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wolf I, Sadetzki S, Catane R, Karasik A
and Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol.
6:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu B, Fan Z, Edgerton SM, Deng XS,
Alimova IN, Lind SE and Thor AD: Metformin induces unique
biological and molecular responses in triple negative breast cancer
cells. Cell Cycle. 8:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sachdev D, Singh R, Fujita-Yamaguchi Y and
Yee D: Down-regulation of insulin receptor by antibodies against
the type I insulin-like growth factor receptor: Implications for
anti-insulin-like growth factor therapy in breast cancer. Cancer
Res. 66:2391–2402. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim J, Lim W, Kim EK, Kim MK, Paik NS,
Jeong SS, Yoon JH, Park CH, Ahn SH, Kim LS, et al: Phase II
randomized trial of neoadjuvant metformin plus letrozole versus
placebo plus letrozole for estrogen receptor positive
postmenopausal breast cancer (METEOR). BMC Cancer. 14:1702014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Goodwin PJ, Stambolic V, Lemieux J, Chen
BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA,
Mayer IA, et al: Evaluation of metformin in early breast cancer: A
modification of the traditional paradigm for clinical testing of
anti-cancer agents. Breast Cancer Res Treat. 126:215–220. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ness RB, Grisso JA, Klapper J,
Schlesselman JJ, Silberzweig S, Vergona R, Morgan M and Wheeler JE:
Risk of ovarian cancer in relation to estrogen and progestin dose
and use characteristics of oral contraceptives SHARE Study Group.
Steroid Hormones and Reproductions. Am J Epidemiol. 152:233–241.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J,
Lau S, Pollak MN and Bruchim I: In vitro metformin
anti-neoplastic activity in epithelial ovarian cancer. Gynecol
Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bodmer M, Becker C, Meier C, Jick SS and
Meier CR: Use of metformin and the risk of ovarian cancer: A
case-control analysis. Gynecol Oncol. 123:200–204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Home PD, Kahn SE, Jones NP, Noronha D,
Beck-Nielsen H and Viberti G: ADOPT Study Group; RECORD Steering
Committee: Experience of malignancies with oral glucose-lowering
drugs in the randomised controlled ADOPT (A Diabetes Outcome
Progression Trial) and RECORD (Rosiglitazone Evaluated for
Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes)
clinical trials. Diabetologia. 53:1838–1845. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang ZJ and Li S: The prognostic value of
metformin for cancer patients with concurrent diabetes: A
systematic review and meta-analysis. Diabetes Obes Metab.
16:707–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kumar S, Meuter A, Thapa P, Langstraat C,
Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake
is associated with better survival in ovarian cancer: A
case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pollak M: Metformin and other biguanides
in oncology: Advancing the research agenda. Cancer Prev Res
(Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fogarty S and Hardie DG: Development of
protein kinase activators: AMPK as a target in metabolic disorders
and cancer. Biochim Biophys Acta. 1804:581–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xiao X, He Q, Lu C, Werle KD, Zhao RX,
Chen J, Davis BC, Cui R, Liang J and Xu ZX: Metformin impairs the
growth of liver kinase B1-intact cervical cancer cells. Gynecol
Oncol. 127:249–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Nevadunsky NS, Van Arsdale A, Strickler
HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL and Einstein
P: Metformin use and endometrial cancer survival. Gynecol Oncol.
132:236–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
He X, Esteva FJ, Ensor J, Hortobagyi GN,
Lee MH and Yeung SC: Metformin and thiazolidinediones are
associated with improved breast cancer-specific survival of
diabetic women with HER2+ breast cancer. Ann Oncol.
23:1771–1780. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hou G, Zhang S, Zhang X, Wang P, Hao X and
Zhang J: Clinical pathological characteristics and prognostic
analysis of 1,013 breast cancer patients with diabetes. Breast
Cancer Res Treat. 137:807–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Peeters PJ, Bazelier MT, Vestergaard P,
Leufkens HG, Schmidt MK, de Vries F and De Bruin ML: Use of
metformin and survival of diabetic women with breast cancer. Curr
Drug Saf. 8:357–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xiao Y, Zhang S, Hou G, Zhang X, Hao X and
Zhang J: Clinical pathological characteristics and prognostic
analysis of diabetic women with luminal subtype breast cancer.
Tumour Biol. 35:2035–2045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lega IC, Austin PC, Gruneir A, Goodwin PJ,
Rochon PA and Lipscombe LL: Association between metformin therapy
and mortality after breast cancer: A population-based study.
Diabetes Care. 36:3018–3026. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bayraktar S, Hernadez-Aya LF, Lei X,
Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN and
Gonzalez-Angulo AM: Effect of metformin on survival outcomes in
diabetic patients with triple receptor-negative breast cancer.
Cancer. 118:1202–1211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Currie CJ, Poole CD, Jenkins-Jones S, Gale
EA, Johnson JA and Morgan CL: Mortality after incident cancer in
people with and without type 2 diabetes: Impact of metformin on
survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Romero IL, McCormick A, McEwen KA, Park S,
Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of
type II diabetes and metformin use to ovarian cancer progression,
survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012.
View Article : Google Scholar : PubMed/NCBI
|
